Development asset linked to TESARO Bio Netherlands in public FDA and regional records.
pharma · Ovarian Neoplasms · Stage 3 or 4 Non-mucinous Epithelial Ovarian Cancer
TESARO Bio Netherlands
TESARO Bio Netherlands B.V.
TESARO Bio Netherlands drug portfolio — 23 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
EU HQ
EMA registrant Type
Company details
- Status
- Public
- HQ
- EU
- Programs
- 6
- Drugs
- 23
- Patents
- 0
TESARO Bio Netherlands pipeline
Portfolio lens on 23 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
TESARO Bio Netherlands drug portfolio — 23 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
bevacizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Vascular endothelial growth factor A, long form.
- Target
- Vascular endothelial growth factor A, long form
- Mechanism
- Vascular endothelial growth factor A inhibitor
-
Development asset linked to TESARO Bio Netherlands in public FDA and regional records.
-
Development asset linked to TESARO Bio Netherlands in public FDA and regional records.
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
Development asset linked to TESARO Bio Netherlands in public FDA and regional records.
-
Development asset linked to TESARO Bio Netherlands in public FDA and regional records.
-
dostarlimab
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in TESARO Bio Netherlands's portfolio. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 antagonist
-
Development asset linked to TESARO Bio Netherlands in public FDA and regional records.
-
Development asset linked to TESARO Bio Netherlands in public FDA and regional records.
-
Development asset linked to TESARO Bio Netherlands in public FDA and regional records.
-
Development asset linked to TESARO Bio Netherlands in public FDA and regional records.
-
Development asset linked to TESARO Bio Netherlands in public FDA and regional records.
-
Development asset linked to TESARO Bio Netherlands in public FDA and regional records.
-
Development asset linked to TESARO Bio Netherlands in public FDA and regional records.
-
niraparib
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in TESARO Bio Netherlands's portfolio. Molecular target: Poly [ADP-ribose] polymerase 2.
- Target
- Poly [ADP-ribose] polymerase 2
- Mechanism
- Poly [ADP-ribose] polymerase-1 inhibitor
-
Development asset linked to TESARO Bio Netherlands in public FDA and regional records. Molecular target: Poly [ADP-ribose] polymerase 2.
- Target
- Poly [ADP-ribose] polymerase 2
- Mechanism
- Poly [ADP-ribose] polymerase 2 inhibitor
-
paclitaxel
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
Development asset linked to TESARO Bio Netherlands in public FDA and regional records.
-
Development asset linked to TESARO Bio Netherlands in public FDA and regional records.
-
Development asset linked to TESARO Bio Netherlands in public FDA and regional records.
-
Development asset linked to TESARO Bio Netherlands in public FDA and regional records.
-
Development asset linked to TESARO Bio Netherlands in public FDA and regional records.